Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose determination of TEX + trastuzumab in first-line HER2-positive esophagogastric cancer
2010-021016-41Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Dec 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab in esophageal adenocarcinoma (EAC), gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by University Hospital Odense. Primary endpoints: Maximum tolerated dose (MTD) of TEX + trastuzumab and Toxicity of TEX + trastuzumab. Started Dec 2010; status: completed.
02
Drugs
03
Conditions
esophageal adenocarcinoma (EAC)gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2010-021016-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021016-41.